CXCL12–CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy

BACKGROUND: Pancreatic cancer cells are highly resistant to drug therapy; however, underlying causes remain largely unknown. We hypothesised that the activation of CXCL12–CXCR4 signalling confers drug resistance to pancreatic cancer cells by potentiating survival. CXCR4 is overexpressed in precancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, S, Srivastava, S K, Bhardwaj, A, Owen, L B, Singh, A P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994230/
https://www.ncbi.nlm.nih.gov/pubmed/21045835
http://dx.doi.org/10.1038/sj.bjc.6605968

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994230/
https://www.ncbi.nlm.nih.gov/pubmed/21045835
http://dx.doi.org/10.1038/sj.bjc.6605968

Ejemplares similares